XRad Therapeutics Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
XRad Therapeutics General Information
Description
Operator of a biotechnology company intended to develop dual kinase inhibitors for treating cancer. The company develops dual inhibitors of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase, evaluating the potential benefits of using them in combination with targeted radionuclides, checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase (PARP) inhibitors, and antibody-drug conjugates (ADCs), providing healthcare professionals with therapeutics for the treatment of metastatic, locally-advanced, or recurrent solid tumors.
Contact Information
Website
www.xradtx.comCorporate Office
- 7 Essex Street
- Suite 3B
- New York, NY 10002
- United States
Corporate Office
- 7 Essex Street
- Suite 3B
- New York, NY 10002
- United States
XRad Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 09-Oct-2024 | Completed | Out of Business | |||
| 2. Later Stage VC (Series B) | 24-Feb-2021 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 19-Dec-2017 | $499K | $499K | Completed | Clinical Trials - Phase 1 |
XRad Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
XRad Therapeutics Patents
XRad Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024186805-A1 | Methods of treating cancer | Inactive | 06-Mar-2023 | ||
| EP-4288423-A1 | Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy | Inactive | 03-Feb-2021 | ||
| EP-4288423-A4 | Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy | Inactive | 03-Feb-2021 | ||
| US-20250268873-A1 | Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy | Pending | 03-Feb-2021 | ||
| WO-2022169840-A1 | Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy | Inactive | 03-Feb-2021 | C07D471/04 |
XRad Therapeutics FAQs
-
When was XRad Therapeutics founded?
XRad Therapeutics was founded in 2016.
-
Where is XRad Therapeutics headquartered?
XRad Therapeutics is headquartered in New York, NY.
-
What industry is XRad Therapeutics in?
XRad Therapeutics’s primary industry is Biotechnology.
-
Is XRad Therapeutics a private or public company?
XRad Therapeutics is a Private company.
-
What is XRad Therapeutics’s current revenue?
The current revenue for XRad Therapeutics is .
-
How much funding has XRad Therapeutics raised over time?
XRad Therapeutics has raised $2M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process